Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
…iated during follow-up—may still exist. At baseline, the use of sodium–glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists, and glucagon-like pept…
…dications, such as sodium–glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists, which have been shown to reduce cardiovascular and renal outco…
…d significantly after intervention (−2.0% per quarter; p=0.02). Insulin prescribing rates did not change throughout the study period. T…
…) is an alternative. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been associated with reduced headache burden and visual s…
…Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have rapidly emerged as highly effective pharmacological tools…
… in modern medicine. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), currently licensed for the treatment of type 2 diabetes melli…
…will benefit most from medications such as SGLT2-inhibitors and GLP1-RA (unpublished). Thirdly, we were unable to assess on the predict…
… challenge globally. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated significant efficacy in weight loss; however…